10
Treatment
Figure 2. Second-Line Treatment Options for Patients with
Stage IV NSCLC Without Driver Alterations
Patients with stage IV NSCLC,
PS 0–1
SCC or non-SCC
Driver alteration
a
negative
Received first-line platinum
doublet chemotherapy
Negative or unknown PD-L1 Positive PD-L1
S
Single-agent nivolumab
S
Single-agent nivolumab
S
Single-agent atezolizumab
S
Single-agent atezolizumab
S
Single-agent
pembrolizumab
M
Single-agent docetaxel
(If not received in first-line)
S
S
Single-agent pemetrexed
(If not recieved in first-line)
W
W
Paclitaxel + bevacizumab
(If not received in first-line)
M
Single-agent docetaxel
(If not received in first-line)
Single-agent permetrexed
(If not received in first-line)
Paclitaxel + bevacizumab
(If not received in first-line)
For patients with contraindications to
immunotherapy
For patients with contraindications to
immunotherapy
For patients with non-SCC only
For patients with non-SCC only
